Mizuho Securities Usa Exits Position in Organovo Holdings Inc (ONVO)

Organovo Holdings Inc (ONVO) : Mizuho Securities Usa has sold out all of its stake in Organovo Holdings Inc during the most recent quarter, according to the disclosure filed by the company on Apr 21, 2016 with the SEC. The investment management company has sold out 66,300 shares of Organovo Holdings Inc which is valued at $184,314.

Organovo Holdings Inc closed down -0.02 points or -0.71% at $2.79 with 5,22,977 shares getting traded on Wednesday. Post opening the session at $2.8, the shares hit an intraday low of $2.75 and an intraday high of $2.84 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Penbrook Management boosted its stake in ONVO in the latest quarter, The investment management firm added 24,550 additional shares and now holds a total of 196,225 shares of Organovo Holdings Inc which is valued at $545,506. Organovo Holdings Inc makes up approx 0.59% of Penbrook Management’s portfolio.Cue Financial Group reduced its stake in ONVO by selling 1,500 shares or 4.11% in the most recent quarter. The Hedge Fund company now holds 35,000 shares of ONVO which is valued at $95,550. Organovo Holdings Inc makes up approx 0.08% of Cue Financial Group’s portfolio. Simplex Trading added ONVO to its portfolio by purchasing 20,929 company shares during the most recent quarter which is valued at $57,136. Organovo Holdings Inc makes up approx 0.01% of Simplex Trading’s portfolio.

Organovo Holdings Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development biological research and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition architecture and function. Its platform NovoGen Bioprinters is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue which can be used for predictive preclinical testing of drug compounds.

Leave a Reply

Organovo Holdings Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Organovo Holdings Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.